|
Mutation Information
|
Mutation Site
|
A181T |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Genotype/Subtype
|
C;D |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Australia |
Literature Information
|
PubMed PMID
|
24329944
|
|
Disease
|
HBV infection
|
|
Published Year
|
2014 |
|
Journal
|
Journal of viral hepatitis |
|
Title
|
Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. |
|
Author
|
Ayres A,Yuen L,Jackson KM,Manoharan S,Glass A,Maley M,Yoo W,Hong SP,Kim SO,Luciani F,Bowden DS,Bayliss J,Levy MT,Locarnini SA |
|
Evidence
|
UDPS showed that LMV therapy resulted in increased viral quasispecies diversity and positive selection of HBV variants with reverse transcriptase amino acid substitutions at sites associated with primary LMV resistance (rtM204I/V and rtA181T) in four (19%) women.
|
|
|
HBV Mutation Detail Information